- Home
- CHRS vs WNEB Comparison
CHRS vs WNEB Comparison
Compare CHRS & WNEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- WNEB
- Stock Information
- Founded
- CHRS 2010
- WNEB 1853
- Country
- CHRS United States
- WNEB United States
- Employees
- CHRS N/A
- WNEB N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- WNEB Savings Institutions
- Sector
- CHRS Health Care
- WNEB Finance
- Exchange
- CHRS Nasdaq
- WNEB Nasdaq
- Market Cap
- CHRS 84.2M
- WNEB 195.7M
- IPO Year
- CHRS 2014
- WNEB N/A
- Fundamental
- Price
- CHRS $0.90
- WNEB $9.80
- Analyst Decision
- CHRS Buy
- WNEB Buy
- Analyst Count
- CHRS 3
- WNEB 3
- Target Price
- CHRS $4.68
- WNEB $9.75
- AVG Volume (30 Days)
- CHRS 1.3M
- WNEB 204.7K
- Earning Date
- CHRS 08-07-2025
- WNEB 07-22-2025
- Dividend Yield
- CHRS N/A
- WNEB 2.83%
- EPS Growth
- CHRS N/A
- WNEB N/A
- EPS
- CHRS N/A
- WNEB 0.53
- Revenue
- CHRS $272,251,000.00
- WNEB $72,966,000.00
- Revenue This Year
- CHRS N/A
- WNEB N/A
- Revenue Next Year
- CHRS $99.43
- WNEB $7.94
- P/E Ratio
- CHRS $2.07
- WNEB $18.42
- Revenue Growth
- CHRS 19.87
- WNEB N/A
- 52 Week Low
- CHRS $0.66
- WNEB $6.89
- 52 Week High
- CHRS $2.43
- WNEB $10.09
- Technical
- Relative Strength Index (RSI)
- CHRS 59.04
- WNEB 59.04
- Support Level
- CHRS $0.73
- WNEB $9.28
- Resistance Level
- CHRS $0.82
- WNEB $10.01
- Average True Range (ATR)
- CHRS 0.04
- WNEB 0.27
- MACD
- CHRS 0.02
- WNEB 0.07
- Stochastic Oscillator
- CHRS 88.02
- WNEB 81.41
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.